Uppsala Monitoring Centre
Birgitta Lindner has a diverse work experience spanning over several years. Birgitta began their career in 1989 as an Authorized Public Accountant at Ernst & Young, where they worked until 1998. After that, they joined RTM Norden AB as a Board Member from 1999 to 2001. Later, from 1998 to 2001, they served as the Chief Financial Officer at SYSteam Udac AB. In 2001, they became the Accounting Director at Fresenius Kabi AB, where they worked until 2006. During this time, Lindner also served as a Board Member at Procordias Pensionsstiftelse II from 2002 to 2006. In 2006, they joined Uppsala Monitoring Centre as the Chief Financial Officer, a role they held until May 2023. Additionally, they have also served in various roles at Uppsala Monitoring Centre, including Deputy Director from 2020 and Acting Director from January 2022 to February 2023.
Birgitta Lindner is currently pursuing a Master of Philosophy degree in Philosophy at Umeå University, with an expected completion date in 2025. Prior to this, they obtained a basic level degree in Psychology from Mid Sweden University between 2023 and 2024. In 1989, they earned a BA degree in Business and Administration from Uppsala University. Additionally, they hold a Bachelor's degree in Business Administration and Management, General from Lund University School of Economics and Management, achieved from 1986 to 1987. There is no available information regarding their education prior to attending Gottsundaskolan.
This person is not in any teams
Uppsala Monitoring Centre
Uppsala Monitoring Centre is an independent, non-profit foundation and a centre for international service and scientific research in the field of pharmacovigilance. We advance the safety of patients by exploring and understanding the risks and benefits of medicines, with the ultimate aim of helping patients and physicians make wise therapeutic decisions. For more than 40 years, we have provided scientific leadership and operational support to the WHO Programme for International Drug Monitoring, expanding the global pharmacovigilance network to reach more than 95% of the world’s population. We create partnerships that bring together resources, expertise, and a shared vision of patient safety. Today, we continue to build a global drug safety culture by supporting and engaging all pharmacovigilance stakeholders, from national centres to regulators, academia and the pharma industry.